Rituximab Therapy in Myasthenia Gravis

Efficacy and Safety Considerations

• Rituximab demonstrates particular effectiveness in MuSK-antibody positive Myasthenia Gravis with good tolerability, as reported by the American Academy of Neurology 1
• The standard 375 mg/m² weekly for 4 weeks regimen is well-established and shows similar efficacy with potentially reduced toxicity in Myasthenia Gravis patients, according to the American College of Rheumatology 1

Drug Interactions and Precautions

• The National Comprehensive Cancer Network recommends avoiding medications that worsen myasthenia, such as beta-blockers, IV magnesium, fluoroquinolones, aminoglycosides, and macrolide antibiotics, when using rituximab in Myasthenia Gravis patients 2